Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Published:2015-05-14 Issue:20 Volume:372 Page:1909-1919
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Mayer Robert J.,Van Cutsem Eric,Falcone Alfredo,Yoshino Takayuki,Garcia-Carbonero Rocio,Mizunuma Nobuyuki,Yamazaki Kentaro,Shimada Yasuhiro,Tabernero Josep,Komatsu Yoshito,Sobrero Alberto,Boucher Eveline,Peeters Marc,Tran Ben,Lenz Heinz-Josef,Zaniboni Alberto,Hochster Howard,Cleary James M.,Prenen Hans,Benedetti Fabio,Mizuguchi Hirokazu,Makris Lukas,Ito Masanobu,Ohtsu Atsushi

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1414325

Cited by 1095 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysis;The Lancet Regional Health - Europe;2024-11

2. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?;Critical Reviews in Oncology/Hematology;2024-10

3. Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in a Refractory Colorectal and Appendiceal Carcinomatosis: Secondary Analysis of the US PIPAC Collaborative Phase 1 Trial;Annals of Surgical Oncology;2024-09-13

4. Predictive and Prognostic Role of Systemic Immune-Inflammation Index (SII) in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil;Biomedicines;2024-09-11

5. Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib;The Oncologist;2024-09-07